Pfizer (PFE) Stock Price, News & Analysis

Company Overview

Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development and commercialization of medicines and vaccines. The company’s core activities span research and development, manufacturing, and marketing of products across a wide range of therapeutic areas. Pfizer’s portfolio addresses conditions in immunology, oncology, cardiology, endocrinology, rare diseases, neuroscience and infectious diseases, with a focus on delivering innovative treatments that improve patient outcomes.

Founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, Pfizer began as a fine-chemicals firm and soon expanded into large-scale pharmaceutical manufacturing. Over its history, the company has grown through a combination of internal R&D efforts and strategic acquisitions, including the 2009 purchase of Wyeth and the 2015 acquisition of Hospira. These moves strengthened its vaccine and sterile injectable businesses and broadened its therapeutic capabilities.

Today, Pfizer is known for its leading vaccines, such as the pneumococcal Prevnar franchise, and for breakthrough therapies in oncology, including Ibrance and Xtandi (the latter developed in collaboration with Astellas). The company’s research pipeline also features antiviral therapies, immuno-oncology candidates and precision medicines for genetic disorders. Collaboration with biotech partners and academia plays a central role in Pfizer’s innovation strategy, helping to advance early-stage science toward clinical development.

With commercial operations in more than 125 countries and research centers in the United States, Europe and Asia, Pfizer maintains a broad geographic footprint. Under the leadership of Chairman and CEO Albert Bourla, who took the helm in 2019, the company continues to prioritize investment in R&D, strategic alliances and sustainable manufacturing practices. Pfizer’s mission remains focused on leveraging scientific excellence to address global health challenges and deliver therapies that make a meaningful difference in patients’ lives.

Key Stats

• Today's Range: $24.26 to $25.35
• 50-Day Range: $22.01 to $24.85
• 52-Week Range: $20.92 to $31.54
• Volume: 59.11 million shs
• Average Volume: 41.52 million shs
• Market Capitalization: $142.30 billion
• P/E Ratio: 18.14
• Dividend Yield: 6.87%
• Price Target: $29.17
• Consensus Rating: Moderate Buy

Pfizer Stock Analysis - MarketRank™

Pfizer scored higher than 98% of companies evaluated by MarketBeat, and ranked 33rd out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pfizer has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 3 buy ratings, 8 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Pfizer has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 2.71%

Earnings Growth

Earnings for Pfizer are expected to grow by 2.71% in the coming year, from $2.95 to $3.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pfizer is 18.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.87.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pfizer is 18.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.31.

Price to Earnings Growth Ratio

Pfizer has a PEG Ratio of 0.88. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Pfizer has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.88% of the float of Pfizer has been sold short.

Short Interest Ratio / Days to Cover

Pfizer has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pfizer has recently increased by 1.66%, indicating that investor sentiment is decreasing.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Leadership

Pfizer is a leading dividend payer. It pays a dividend yield of 7.11%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Pfizer has been increasing its dividend for 16 years.

Dividend Coverage

The dividend payout ratio of Pfizer is 124.64%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Pfizer will have a dividend payout ratio of 56.77% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -2.61

Percentage of Shares Shorted

1.88% of the float of Pfizer has been sold short.

Short Interest Ratio / Days to Cover

Pfizer has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pfizer has recently increased by 1.66%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.06

News Sentiment

Pfizer has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 87 news articles for Pfizer this week, compared to 64 articles on an average week.

Search Interest

Only 165 people have searched for PFE on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.

MarketBeat Follows

Only 48 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pfizer insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.06% of the stock of Pfizer is held by insiders.

Percentage Held by Institutions

68.36% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PFE Stock Analysis - Frequently Asked Questions

How have PFE shares performed this year?

Pfizer's stock was trading at $26.53 at the beginning of the year. Since then, PFE stock has decreased by 5.7% and is now trading at $25.03.
View the best growth stocks for 2025 here.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) announced its earnings results on Tuesday, April, 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business's revenue was down 7.8% compared to the same quarter last year.
Read the conference call transcript.

Does Pfizer have any subsidiaries?

Pfizer subsidiaries include ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and others.

Who are Pfizer's major shareholders?

Top institutional investors of Pfizer include Stonebridge Capital Management Inc., Park National Corp OH, Cullen Investment Group LTD. and Stonehearth Capital Management LLC. Insiders that own company stock include Pfizer Inc, Ronald E Blaylock and Scott Gottlieb.
View institutional ownership trends.

How do I buy shares of Pfizer?

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include Scilex (SCLX), Salesforce (CRM), Chevron (CVX), AbbVie (ABBV), Johnson & Johnson (JNJ), Meta Platforms (META) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 4/29/2025
• Record date for 6/13 Dividend: 5/09/2025
• Ex-Dividend for 6/13 Dividend: 5/09/2025
• Dividend Payable: 6/13/2025
• Today: 7/01/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:PFE
• CIK: 78003
• Web: www.pfizer.com
• Phone: (212) 733-2323
• Fax: 302-655-5049
• Employees: 81,000
• Year Founded: 1849

Price Target and Rating

• Average Stock Price Target: $29.17
• High Stock Price Target: $34.00
• Low Stock Price Target: $24.00
• Potential Upside/Downside: +16.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.53
• Research Coverage: 15 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.38
• Trailing P/E Ratio: 18.16
• Forward P/E Ratio: 8.50
• P/E Growth: 0.88
• Net Income: $8.03 billion
• Net Margins: 12.62%
• Pretax Margin: 11.83%
• Return on Equity: 20.33%
• Return on Assets: 8.53%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 1.26
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $63.63 billion
• Price / Sales: 2.24
• Cash Flow: $4.52 per share
• Price / Cash Flow: 5.54
• Book Value: $15.62 per share
• Price / Book: 1.60

Miscellaneous

• Outstanding Shares: 5,685,370,000
• Free Float: 5,681,955,000
• Market Cap: $142.50 billion
• Optionable: Optionable
• Beta: 0.57